Description: Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Home Page: www.astellas.com
2-5-1, Nihonbashi-Honcho
Tokyo,
103-8411
Japan
Phone:
81 3 3244 3000
Officers
| Name | Title |
|---|---|
| Mr. Naoki Okamura BSc | President, CEO & Director |
| Mr. Atsushi Kitamura | Senior Executive Officer & CFO |
| Nobue Yasuda | General Manager of Finance & Accounting Department |
| Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer |
| Ms. Catherine B. Levitt J.D. | General Counsel |
| Mr. Katsuyoshi Sugita | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director |
| Mr. Stig Ogata | Vice President of Corporate Communications |
| Ms. Tatjana Dragovic | Senior VP and Head of Ethics & Compliance |
| Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive |
| Jun Kono | Senior Executive Officer & Head of Japan Commercial |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 12.3762 |
|---|---|
| Trailing PE: | 51.85 |
| Price-to-Book MRQ: | 1.8473 |
| Price-to-Sales TTM: | 0.0105 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 14754 |